Fortress Biotech, Inc. FBIOP Stock
Fortress Biotech, Inc. Price Chart
Fortress Biotech, Inc. FBIOP Financial and Trading Overview
Fortress Biotech, Inc. stock price | 5.79 USD |
Previous Close | 17.4 USD |
Open | 17.3 USD |
Bid | 0 USD x 1000 |
Ask | 0 USD x 4000 |
Day's Range | 17.11 - 18.23 USD |
52 Week Range | 15.65 - 22.42 USD |
Volume | 6.03K USD |
Avg. Volume | 9.13K USD |
Market Cap | 94.58M USD |
Beta (5Y Monthly) | 2.007746 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.863 USD |
Forward Dividend & Yield | 2.34 (13.20%) |
Ex-Dividend Date | June 14, 2023 |
1y Target Est | N/A |
FBIOP Valuation Measures
Enterprise Value | 2.32B USD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 1.4721601 |
Price/Book (mrq) | 60.758625 |
Enterprise Value/Revenue | 36.14 |
Enterprise Value/EBITDA | -11.183 |
Trading Information
Fortress Biotech, Inc. Stock Price History
Beta (5Y Monthly) | 2.007746 |
52-Week Change | 0.97% |
S&P500 52-Week Change | 20.43% |
52 Week High | 22.42 USD |
52 Week Low | 15.65 USD |
50-Day Moving Average | 17.76 USD |
200-Day Moving Average | 18.99 USD |
FBIOP Share Statistics
Avg. Volume (3 month) | 9.13K USD |
Avg. Daily Volume (10-Days) | 14.31K USD |
Shares Outstanding | 56.68M |
Float | 87.54M |
Short Ratio | 0.03 |
% Held by Insiders | 0% |
% Held by Institutions | 1.53% |
Shares Short | 324 |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | 1137.00% |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -143.74% |
Operating Margin (ttm) | -334.89% |
Gross Margin | -159.43% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -40.052% |
Return on Equity (ttm) | -205.80% |
Income Statement
Revenue (ttm) | 64.25M USD |
Revenue Per Share (ttm) | 0.69 USD |
Quarterly Revenue Growth (yoy) | -48.10% |
Gross Profit (ttm) | N/A |
EBITDA | -207618000 USD |
Net Income Avi to Common (ttm) | -92352000 USD |
Diluted EPS (ttm) | -0.863 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 152.48M USD |
Total Cash Per Share (mrq) | 1.14 USD |
Total Debt (mrq) | 125.53M USD |
Total Debt/Equity (mrq) | 633.8 USD |
Current Ratio (mrq) | 1.563 |
Book Value Per Share (mrq) | 0.29 |
Cash Flow Statement
Operating Cash Flow (ttm) | -175760992 USD |
Levered Free Cash Flow (ttm) | -90323128 USD |
Profile of Fortress Biotech, Inc.
Country | United States |
State | FL |
City | Bay Harbor Islands |
Address | 1111 Kane Concourse |
ZIP | 33154 |
Phone | 781 652 4500 |
Website | https://www.fortressbiotech.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 187 |
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Q&A For Fortress Biotech, Inc. Stock
What is a current FBIOP stock price?
Fortress Biotech, Inc. FBIOP stock price today per share is 5.79 USD.
How to purchase Fortress Biotech, Inc. stock?
You can buy FBIOP shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Fortress Biotech, Inc.?
The stock symbol or ticker of Fortress Biotech, Inc. is FBIOP.
Which industry does the Fortress Biotech, Inc. company belong to?
The Fortress Biotech, Inc. industry is Biotechnology.
How many shares does Fortress Biotech, Inc. have in circulation?
The max supply of Fortress Biotech, Inc. shares is 5.37M.
What is Fortress Biotech, Inc. Price to Earnings Ratio (PE Ratio)?
Fortress Biotech, Inc. PE Ratio is now.
What was Fortress Biotech, Inc. earnings per share over the trailing 12 months (TTM)?
Fortress Biotech, Inc. EPS is -0.863 USD over the trailing 12 months.
Which sector does the Fortress Biotech, Inc. company belong to?
The Fortress Biotech, Inc. sector is Healthcare.